Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2024
Fruquintinib for patients with previously treated metastatic colorectal cancer
8 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2024
Bimekizumab for the treatment of patients with moderate to severe hidradenitis suppurativa
7 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2024
October 2024 decisions
7 October 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 07 Oct 2024
New flexible service through our scientific advice program
26 September 2024 - Drug sponsors can now request a flexible service through our scientific advice program that can include ...
Posted by Michael Wonder on 04 Oct 2024
Netarsudil mesylate with latanoprost for the treatment of patients with primary open-angle glaucoma or ocular hypertension
2 October 2024 - NiCE has published final evidence-based recommendations on the use of netarsudil mesylate with latanoprost (Roclanda) for ...
Posted by Michael Wonder on 02 Oct 2024
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, ESR1 mutation positive, HER2 negative breast cancer after at least one endocrine treatment
1 October 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 02 Oct 2024
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of ...
Posted by Michael Wonder on 01 Oct 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - May 2024 PBAC meeting
1 October 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the May 2024 PBAC ...
Posted by Michael Wonder on 29 Sep 2024
Cabotegravir for the prevention of HIV-1 infection in adults and adolescents
26 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 24 Sep 2024
Merck receives positive EU CHMP opinions for Keytruda (pembrolizumab) regimens as treatment for patients with two types of gynaecologic cancers
20 September 2024 - Positive opinion granted for Keytruda plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Posted by Michael Wonder on 23 Sep 2024
Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis
23 September 2024 - New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and ...
Posted by Michael Wonder on 23 Sep 2024
Henlius and Intas receive positive CHMP opinion for Hetronifly in European markets as first-line treatment for adult patients with extensive-stage small cell lung cancer
21 September 2024 - Hetronifly (serplulimab) is expected to become the first anti-PD-1 monoclonal antibody available in Europe for first-line treatment ...
Posted by Michael Wonder on 20 Sep 2024
Dupixent (dupilumab) recommended for EU approval by the CHMP to treat eosinophilic oesophagitis in children as young as 1 year old
20 September 2024 - Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved ...
Posted by Michael Wonder on 20 Sep 2024
AbbVie receives positive CHMP opinion for mirvetuximab soravtansine (Elahere) for the treatment of certain adult ovarian cancer
20 September 2024 - AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the marketing authorisation of ...